About
Read more:
About nanologica
Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances.
Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines.
The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022. The Group includes Nanologica AB (publ) and Syntagon AB.
Nanologica AB (publ)
Nanologica AB (publ) develops, manufactures and sells purification media for preparative chromatography to pharmaceutical manufacturers globally. The main product NLAB Saga® is a silica-based purification media with high chemical and mechanical stability specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues (e.g. Ozempic and Wegovy). Thanks to its efficient and long-lasting purification, NLAB Saga® can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for peptide drugs for the treatment of diabetes and obesity.
A proprietary production method allows us to precisely control the shape, size, porosity and surface properties of silica particles, giving us the opportunity to create first-class products. Thanks to its efficient and long-lasting purification, NLAB Saga® can increase productivity and reduce costs for pharmaceutical manufacturers
Silica particles are visible as a fine white powder. The particles are spherical, have a smooth surface, and are fully porous creating a large surface area.
Chromatography is a widely used technique for separating components in a mixture. Nanologica is active mainly in preparative chromatography, which is used by pharmaceutical manufacturers for the purification of drugs during production. Our products have been especially developed for the purification of peptide drugs such as insulin and GLP-1 analogues.
Sales are conducted directly and together with partners on all major markets – India, China, the US, and Europe.
Apart from silica, Nanologica carries a product range of chromatography media and is continuously developing complementary products and services to meet our customers’ needs.
At the head office in Södertälje, Sweden, there is development of new products, customer support in the form of application support and method development, as well as small-scale production of silica. For large-scale production, the company works together with partners. Large-scale production of silica takes place at a contract manufacturer in the UK in a factory with multi-ton scale capacity.
Nanologica’s share (NICA) is listed on Nasdaq Stockholm Main Market since 2022.
Syntagon AB
Syntagon AB is part of the Nanologica Group and is a Swedish CDMO (contract developing and manufacturing organization) of drug molecules. The company offers services in API development, GMP manufacturing, and advanced analysis and purification.
The plant in Södertälje specializes in API development and API production with the capacity to take active pharmaceutical ingredients (APIs) from preclinical to clinical studies and further into commercial manufacturing.